Abstract
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing antibodies (bnAbs), CH01 and VRC-CH31, from two clonal lineages of memory B cells with distinct specificities (variable loop 1 and 2 [V1V2] conformational specificity and CD4-binding site specificity, respectively) that recapitulate 95% of CH0219 serum neutralization breadth. These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
MeSH terms
-
AIDS Vaccines / immunology
-
Antibodies, Neutralizing / genetics
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Neutralizing / metabolism
-
Antibody Specificity* / immunology
-
B-Lymphocytes / immunology
-
Binding Sites
-
CD4 Antigens / chemistry
-
CD4 Antigens / metabolism
-
Epitopes / chemistry
-
HIV Antibodies / genetics
-
HIV Antibodies / immunology*
-
HIV Antibodies / metabolism
-
HIV Envelope Protein gp120 / chemistry
-
HIV Envelope Protein gp120 / immunology
-
HIV Infections / immunology
-
HIV-1 / immunology*
-
Humans
-
Immunoglobulin Variable Region / chemistry
-
Immunoglobulin Variable Region / genetics
-
Neutralization Tests
-
Phylogeny
Substances
-
AIDS Vaccines
-
Antibodies, Neutralizing
-
CD4 Antigens
-
Epitopes
-
HIV Antibodies
-
HIV Envelope Protein gp120
-
Immunoglobulin Variable Region